Cost of Revenue Comparison: AstraZeneca PLC vs GSK plc

Cost of Revenue: AstraZeneca vs GSK

In the competitive landscape of the pharmaceutical industry, understanding cost structures is crucial. From 2014 to 2023, AstraZeneca PLC and GSK plc have shown distinct trends in their cost of revenue. AstraZeneca's cost of revenue saw a significant increase of approximately 115% from 2014 to 2021, peaking in 2021. However, by 2023, it had decreased by about 35% from its peak. In contrast, GSK's cost of revenue remained relatively stable, with a modest increase of around 17% over the same period, peaking in 2019. This stability suggests a consistent cost management strategy. The data highlights AstraZeneca's fluctuating costs, possibly due to strategic investments or market dynamics, while GSK's steadiness may reflect a more controlled approach. These insights are vital for investors and stakeholders aiming to understand the financial health and strategic directions of these pharmaceutical giants.